Novo Nordisk to pay $2 billion for new weight loss drug

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup